Tyr20
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr20  -  IFITM3 (human)

Site Information
NSGQPPNyEMLkEEH   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 463584

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 , 5 , 6 ) , mass spectrometry ( 2 , 4 , 7 , 8 , 9 , 10 , 11 ) , microscopy-colocalization with upstream kinase ( 6 ) , mutation of modification site ( 1 , 3 , 5 , 6 ) , phospho-antibody ( 3 , 5 ) , western blotting ( 1 , 5 , 6 )
Disease tissue studied:
HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, triple negative ( 2 ) , colorectal cancer ( 8 ) , liver cancer ( 1 , 3 , 7 ) , cholangiocellular carcinoma ( 7 ) , hepatocellular carcinoma ( 1 , 3 )
Relevant cell line - cell type - tissue:
breast ( 2 ) , colon ( 8 ) , Flp-In T-Rex-293 (epithelial) ( 1 ) , HEK293T (epithelial) ( 5 , 6 ) , HeLa (cervical) ( 4 , 6 ) , Huh7 (hepatic) ( 1 , 3 ) , Jurkat (T lymphocyte) ( 9 , 10 ) , liver ( 7 ) , SYF (fibroblast) ( 5 ) , TERT20 ('stem, mesenchymal') ( 11 )

Upstream Regulation
Regulatory protein:
Fyn iso2 (human) ( 6 ) , Fyn iso3 (human) ( 6 )
Putative in vivo kinases:
Fyn (human) ( 5 , 6 )
Treatments:
genistein ( 6 ) , IFN-alpha ( 6 ) , PP2 ( 6 ) , siRNA ( 6 ) , U0126 ( 6 ) , vanadate ( 6 )

Downstream Regulation
Effects of modification on IFITM3:
activity, induced ( 6 ) , intracellular localization ( 1 , 3 , 5 , 6 ) , ubiquitination ( 5 )
Effects of modification on biological processes:
endocytosis, inhibited ( 5 )

References 

1

Zhao X, et al. (2017) Identification of residues controlling restriction versus enhancing activities of IFITM proteins on the entry of human coronaviruses. J Virol
29263263   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

3

Narayana SK, et al. (2015) The Interferon-induced Transmembrane Proteins, IFITM1, IFITM2, and IFITM3 Inhibit Hepatitis C Virus Entry. J Biol Chem 290, 25946-59
26354436   Curated Info

4

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

5

Chesarino NM, McMichael TM, Hach JC, Yount JS (2014) Phosphorylation of the antiviral protein interferon-inducible transmembrane protein 3 (IFITM3) dually regulates its endocytosis and ubiquitination. J Biol Chem 289, 11986-92
24627473   Curated Info

6

Jia R, et al. (2012) The N-terminal region of IFITM3 modulates its antiviral activity by regulating IFITM3 cellular localization. J Virol 86, 13697-707
23055554   Curated Info

7

Gu TL, et al. (2011) Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 6, e15640
21253578   Curated Info

8

Tucker M (2010) CST Curation Set: 10846; Year: 2010; Biosample/Treatment: tissue, colon/untreated; Disease: colorectal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

9

Guo A (2010) CST Curation Set: 9182; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

10

Guo A (2010) CST Curation Set: 9181; Year: 2010; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

11

Thingholm TE, et al. (2008) TiO2-Based Phosphoproteomic Analysis of the Plasma Membrane and the Effects of Phosphatase Inhibitor Treatment. J Proteome Res 7, 3304-3313
18578522   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.